Compass Therapeutics (CMPX) Operating Leases (2023 - 2025)
Historic Operating Leases for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $9.9 million.
- Compass Therapeutics' Operating Leases rose 4347.83% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 4347.83%. This contributed to the annual value of $6.3 million for FY2024, which is 107462.69% up from last year.
- Latest data reveals that Compass Therapeutics reported Operating Leases of $9.9 million as of Q3 2025, which was up 4347.83% from $9.9 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Operating Leases registered a high of $9.9 million during Q2 2025, and its lowest value of $536000.0 during Q4 2023.
- In the last 3 years, Compass Therapeutics' Operating Leases had a median value of $2.6 million in 2023 and averaged $4.5 million.
- Examining YoY changes over the last 5 years, Compass Therapeutics' Operating Leases showed a top increase of 107462.69% in 2024 and a maximum decrease of 5358.36% in 2024.
- Quarter analysis of 3 years shows Compass Therapeutics' Operating Leases stood at $536000.0 in 2023, then skyrocketed by 1074.63% to $6.3 million in 2024, then surged by 56.72% to $9.9 million in 2025.
- Its Operating Leases stands at $9.9 million for Q3 2025, versus $9.9 million for Q2 2025 and $6.4 million for Q1 2025.